France Pulmonary Arterial Hypertension Market Size & Outlook
France pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
France pulmonary arterial hypertension market highlights
- The France pulmonary arterial hypertension market generated a revenue of USD 330.6 million in 2023 and is expected to reach USD 479.1 million by 2030.
- The France market is expected to grow at a CAGR of 5.4% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 330.6 million |
| Market revenue in 2030 | USD 479.1 million |
| Growth rate | 5.4% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, France accounted for 4.5% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Sweden is the fastest growing regional market in Europe and is projected to reach USD 133.7 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 46.13% in 2023. Horizon Databook has segmented the France pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
France PAH market is expected to grow at a steady rate during the forecast period. The incidence rate of pulmonary arterial hypertension in France is rare, but it holds a high economic burden on the economy.
Increasing incidence of respiratory illness in French population coupled with growing per capita expenditure on pulmonary arterial hypertension market is anticipated to drive the growth of the market in this region.
Growing awareness related to PAH is anticipated to bolster the market growth in France such as 13th November is recognized as an awareness for the PAH month in France. This initiative has been taken by the Pulmonary hypertension Association. In France, the National Plans for Rare Diseases promotes equal access to diagnosis and care in the country.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
France Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
